Thema: VIMRxyn effektiv gegen Glioblastom?
VIMRxyn effektiv gegen Glioblastom?
Alexandra Minkus
05.10.2000 16:12:12
Gibt es unter Euch GBM-Patienten, die man erfolgreich mit Hypericin (VIMRxyn)
behandelte. Wo kann ich "reines" Hypericin beziehen? Was kostet es? Wer ist ein
Hypericin-Spezialist? Vielen Dank! Alex
Quelle:
Neurosurgery. 1994 Oct;35(4):705-9; discussion 709-10.
Hypericin: a potential antiglioma therapy.
Couldwell WT, et al.
VIMRX Successfully Completes Phase I/II Clinical Study Of VIMRxyn - synthetic hypericin - for the Treatment of Glioblastoma Brain Cancer
Investigators Pleased with Safety and Report Antitumor Activity
WILMINGTON, Del. - (BW HealthWire) - VIMRX Pharmaceuticals Inc. announced today that they have successfully completed a Phase I/II study of VIMRxyn(R) (synthetic hypericin) for the treatment of glioblastoma, a highly malignant form of brain tumor.
The company reports encouraging safety data of the compound, noting that there was minimal toxicity other than the well-known and manageable photo-sensitivity associated with hypericin. At a recent investigator meeting to review the clinical data, the independent clinical trial physicians agreed that VIMRxyn(R) was safe at the doses studied, and that an antiglioma effect was observed in several of the patients in the small study. VIMRX is now developing a protocol for a larger Phase II, multi-center study to determine more definitively the efficacy of the compound.
"Glioblastoma is a highly invasive form of brain cancer for which no effective therapy currently exists," said Dr. David A. Jackson, Chief Scientific Officer of VIMRX. "A compound that could retard disease progression and lead to improved quality of life would have a real place in therapy for glioblastoma."
VIMRxyn(R) is a pure, synthetic version of hypericin, a bioactive compound that is found naturally in extracts prepared from the Hypericum family of plants, such as St. John´s wort. In the Phase I/II clinical trial, 17 patients completed three months of treatment with VIMRxyn(R) administered orally once daily. VIMRX is continuing to provide VIMRxyn(R) for those patients who are responding to the treatment beyond the initial three months of therapy set forth by the trial.
The six clinical study sites included New York Medical College in Valhalla; Walt Disney Memorial Cancer Center in Orlando; Tom Baker Cancer Center in Calgary, Canada; USC University Hospital in Los Angeles; University of Washington Medical Center in Seattle; and the Trinity Medical Center in Minot, North Dakota.
VIMRX is also conducting a Phase I/II clinical trial to evaluate the efficacy and tolerability of VIMRxyn(R) as a topically applied, photo-activated therapy for specific skin diseases including psoriasis, cutaneous T-cell lymphoma and warts. This study is being conducted at the University of Pennsylvania Medical Center, Philadelphia, by Alain Rook, M.D., at the Allegheny Hospital, Philadelphia, by Eric Vonderheid, M.D., and at the University Hospital of Cleveland at Case Western Medical Center, by Gary Wood, M.D. and Kevin Cooper, M.D.
VIMRX Pharmaceuticals Inc. is a biotechnology company developing innovative technologies to improve human health. VIMRX´s majority owned subsidiary Nexell Therapeutics Inc., a company formed with Baxter Healthcare Corporation, is focused on cell therapeutics for cancer and other life threatening diseases. Nexell´s lead products, the Isolex(R) Cell Selection Systems, are marketed in numerous European and other countries and are currently under review by the U.S. Food and Drug Administration.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward- looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company´s actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company´s clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company´s periodic reports on Form 10-K and 10-Q, and any prospectus describing the Company´s securities.
behandelte. Wo kann ich "reines" Hypericin beziehen? Was kostet es? Wer ist ein
Hypericin-Spezialist? Vielen Dank! Alex
Quelle:
Neurosurgery. 1994 Oct;35(4):705-9; discussion 709-10.
Hypericin: a potential antiglioma therapy.
Couldwell WT, et al.
VIMRX Successfully Completes Phase I/II Clinical Study Of VIMRxyn - synthetic hypericin - for the Treatment of Glioblastoma Brain Cancer
Investigators Pleased with Safety and Report Antitumor Activity
WILMINGTON, Del. - (BW HealthWire) - VIMRX Pharmaceuticals Inc. announced today that they have successfully completed a Phase I/II study of VIMRxyn(R) (synthetic hypericin) for the treatment of glioblastoma, a highly malignant form of brain tumor.
The company reports encouraging safety data of the compound, noting that there was minimal toxicity other than the well-known and manageable photo-sensitivity associated with hypericin. At a recent investigator meeting to review the clinical data, the independent clinical trial physicians agreed that VIMRxyn(R) was safe at the doses studied, and that an antiglioma effect was observed in several of the patients in the small study. VIMRX is now developing a protocol for a larger Phase II, multi-center study to determine more definitively the efficacy of the compound.
"Glioblastoma is a highly invasive form of brain cancer for which no effective therapy currently exists," said Dr. David A. Jackson, Chief Scientific Officer of VIMRX. "A compound that could retard disease progression and lead to improved quality of life would have a real place in therapy for glioblastoma."
VIMRxyn(R) is a pure, synthetic version of hypericin, a bioactive compound that is found naturally in extracts prepared from the Hypericum family of plants, such as St. John´s wort. In the Phase I/II clinical trial, 17 patients completed three months of treatment with VIMRxyn(R) administered orally once daily. VIMRX is continuing to provide VIMRxyn(R) for those patients who are responding to the treatment beyond the initial three months of therapy set forth by the trial.
The six clinical study sites included New York Medical College in Valhalla; Walt Disney Memorial Cancer Center in Orlando; Tom Baker Cancer Center in Calgary, Canada; USC University Hospital in Los Angeles; University of Washington Medical Center in Seattle; and the Trinity Medical Center in Minot, North Dakota.
VIMRX is also conducting a Phase I/II clinical trial to evaluate the efficacy and tolerability of VIMRxyn(R) as a topically applied, photo-activated therapy for specific skin diseases including psoriasis, cutaneous T-cell lymphoma and warts. This study is being conducted at the University of Pennsylvania Medical Center, Philadelphia, by Alain Rook, M.D., at the Allegheny Hospital, Philadelphia, by Eric Vonderheid, M.D., and at the University Hospital of Cleveland at Case Western Medical Center, by Gary Wood, M.D. and Kevin Cooper, M.D.
VIMRX Pharmaceuticals Inc. is a biotechnology company developing innovative technologies to improve human health. VIMRX´s majority owned subsidiary Nexell Therapeutics Inc., a company formed with Baxter Healthcare Corporation, is focused on cell therapeutics for cancer and other life threatening diseases. Nexell´s lead products, the Isolex(R) Cell Selection Systems, are marketed in numerous European and other countries and are currently under review by the U.S. Food and Drug Administration.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward- looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company´s actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company´s clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company´s periodic reports on Form 10-K and 10-Q, and any prospectus describing the Company´s securities.
Alexandra Minkus
Lea Vierheller
09.10.2000 22:32:34
Hallo Alexandra,
mir ist nur der Fall eines Apothekers bekannt, der sein GBM mittels synth. Hypericin für viele Monate in Schach gehalten hat. Teilremission (!), obwohl da laut Aussage der Ärzte nichts mehr zu machen war. Er hat VIMRxyn+H15 eingenommen und sein Glioblastom ist für 9 Monate vom MRT verschwunden, obwohl es schon riesig war. Die Krankengeschichte wurde auf einem Symposium im März in Hannover vorgestellt. Über 20 GBM-Patienten haben VIMRxyn schon erfolgreich getestet. Vielleicht meldet sich einer. Kennt jemand den Studienleiter des Hypericin-Protokolls oder Bezugsquellen? Der Tagesbedarf von VIMRx-Hypericin soll ueber DM 1000,- kosten. Ist dies korrekt? Bis bald! vielen Dank im voraus!
mir ist nur der Fall eines Apothekers bekannt, der sein GBM mittels synth. Hypericin für viele Monate in Schach gehalten hat. Teilremission (!), obwohl da laut Aussage der Ärzte nichts mehr zu machen war. Er hat VIMRxyn+H15 eingenommen und sein Glioblastom ist für 9 Monate vom MRT verschwunden, obwohl es schon riesig war. Die Krankengeschichte wurde auf einem Symposium im März in Hannover vorgestellt. Über 20 GBM-Patienten haben VIMRxyn schon erfolgreich getestet. Vielleicht meldet sich einer. Kennt jemand den Studienleiter des Hypericin-Protokolls oder Bezugsquellen? Der Tagesbedarf von VIMRx-Hypericin soll ueber DM 1000,- kosten. Ist dies korrekt? Bis bald! vielen Dank im voraus!
Lea Vierheller
R2D2
10.04.2012 20:54:54
Hallo,
gibt es aktuelle Erkenntnisse über die Wirkung oder Wirkungslosigkeit von Hypericin? Nimmt jemand von Euch diese Substanz und kann darüber berichten?
Herzliche Grüße
gibt es aktuelle Erkenntnisse über die Wirkung oder Wirkungslosigkeit von Hypericin? Nimmt jemand von Euch diese Substanz und kann darüber berichten?
Herzliche Grüße
R2D2